Viropro Inc. (VPRO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Viropro Inc. (VPRO) trades at $0.00002 with AI Score 52/100 (Grade B). Viropro Inc. is a biotechnology company specializing in the contract research, development, and manufacture of biotherapeutic proteins. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for VPRO: VPRO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VPRO against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
VPRO: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Viropro Inc. (VPRO) Healthcare & Pipeline Overview
Viropro Inc. operates in the biotechnology sector, focusing on the contract research and development of biotherapeutic proteins, positioning itself as a key player in the production of biosimilars and biogeneric therapeutic solutions.
What Is the Investment Thesis for VPRO?
Viropro Inc. presents a unique investment thesis driven by its strong position in the biotechnology sector and its focus on biotherapeutic proteins. The company's gross margin stands at an impressive 100%, indicating effective cost management and operational efficiency. Key growth catalysts include its ongoing collaboration with Oncobiologics, which may enhance its product offerings and market reach. Additionally, the increasing global demand for biosimilars and biogeneric drugs, projected to grow significantly in the coming years, positions Viropro to capitalize on this trend. However, the company faces risks, including a high profit margin of -176.9%, indicating potential financial instability. Investors may want to evaluate these metrics and the competitive landscape as they evaluate Viropro's potential for growth and profitability.
Based on FMP financials and quantitative analysis
VPRO Key Highlights
Gross margin of 100.0% reflects high operational efficiency in the biotechnology sector.
- Profit margin of -176.9% indicates significant financial challenges that need to be addressed.
- Market Cap is currently at $0.00B, suggesting low market valuation or trading activity.
- Beta of 3.61 indicates high volatility compared to the market, which may affect investor sentiment.
- No dividend yield, reflecting a focus on reinvestment rather than returning capital to shareholders.
Who Are VPRO's Competitors?
VPRO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $442.36 | +4.02% | $239B | 86 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 90 |
| SNY Sanofi | $45.44 | -0.85% | $109B | 58 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VPRO's Key Strengths?
Strong gross margin indicating operational efficiency.
- Expertise in biotherapeutic protein development.
- Established collaborations with industry players.
- Diverse product offerings across multiple therapeutic areas.
What Are VPRO's Weaknesses?
Negative profit margin indicating financial challenges.
- Low market capitalization suggesting limited investor interest.
- High beta indicating volatility and risk.
- Lack of dividend payments may deter income-focused investors.
What Could Drive VPRO Stock Higher?
Expansion of product offerings through collaboration with Oncobiologics, Inc.
- Development of proprietary technologies for biogeneric therapeutic proteins.
- Potential entry into emerging markets to capture new customer segments.
- Increasing demand for biosimilars as healthcare costs rise.
- Advancements in biomanufacturing processes to improve efficiency.
What Are the Key Risks for VPRO?
Financial-distress signal — its Altman Z-Score of -0.92 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Financial instability indicated by a negative profit margin.
- Regulatory challenges that could delay product approvals.
- High volatility in stock price due to low market capitalization.
- Competition from larger biotech firms with more resources.
What Are the Growth Opportunities for VPRO?
- Viropro's expertise in manufacturing biosimilars positions it to capture a significant share of this market as demand for cost-effective alternatives to expensive biologics grows.
- Growth opportunity 2: The rising prevalence of chronic diseases such as diabetes and cancer is driving demand for innovative therapies. Viropro's focus on developing biotherapeutic proteins specifically targeting these conditions aligns with market needs, potentially leading to increased contract research and manufacturing opportunities.
- Growth opportunity 3: Expansion into emerging markets, particularly in Asia-Pacific, where healthcare infrastructure is improving, presents a significant growth avenue. Viropro's operations in Malaysia and potential partnerships in the region could facilitate entry into these high-growth markets, enhancing revenue streams.
- Growth opportunity 4: The company's collaboration with Oncobiologics, Inc. to manufacture monoclonal antibody products is expected to enhance its product portfolio and market reach. This partnership could lead to new revenue streams as the demand for monoclonal antibodies continues to rise in oncology treatments.
- Growth opportunity 5: Technological advancements in biomanufacturing processes may allow Viropro to improve efficiency and reduce costs. By investing in cutting-edge production technologies, the company can enhance its competitive advantage and increase profitability in the long term.
What Threats Does VPRO Face?
- Intense competition in the biotechnology sector.
- Regulatory challenges in drug development and approval.
- Market volatility affecting investor confidence.
- Rapid technological changes requiring continuous innovation.
What Are VPRO's Competitive Advantages?
- Strong expertise in biotherapeutic protein development.
- Proprietary technologies for efficient biomanufacturing.
- Established relationships with key players in the biotech industry.
- Diverse product offerings catering to various therapeutic areas.
- International operations providing a competitive edge in global markets.
What Does VPRO Do?
Founded in San Jose, California, Viropro Inc. has established itself as a significant player in the biotechnology industry, primarily through its subsidiaries. The company is engaged in the contract research, development, and manufacture of biotherapeutic proteins aimed at treating a variety of diseases, including cancer, diabetes, hepatitis, and multiple sclerosis. Over the years, Viropro has evolved by not only developing its proprietary technologies for the industrial production of biogeneric therapeutic proteins but also by offering comprehensive services to biotech and biopharmaceutical companies. Its product offerings include biologics drugs, biosimilars for pre-clinical and clinical trials, and mammalian cell proteins such as monoclonal antibodies and recombinant proteins. Viropro also possesses three proprietary clones, two of which are focused on insulin therapy and one on cancer therapy. The company operates internationally, with facilities and operations in Canada, the United Kingdom, and Malaysia. Viropro has also formed a collaboration agreement with Oncobiologics, Inc. to manufacture and commercialize monoclonal antibody products, further enhancing its market presence and capabilities. As a subsidiary of Alpha Biologics Limited, Viropro Inc. continues to pursue innovative solutions in biotherapeutics, addressing critical healthcare challenges.
What Products and Services Does VPRO Offer?
- Engage in contract research and development of biotherapeutic proteins.
- Manufacture biogeneric therapeutic proteins for various diseases.
- Provide services for pre-clinical and clinical trials.
- Supply mammalian cell proteins, including monoclonal antibodies.
- Own proprietary clones for insulin and cancer therapies.
- Collaborate with other biotech firms for product commercialization.
How Does VPRO Make Money?
- Generate revenue through contract research and manufacturing services.
- Develop and sell biotherapeutic proteins and biosimilars.
- Engage in partnerships for the commercialization of biopharmaceutical products.
- Utilize proprietary technologies for efficient production.
- Focus on international markets to expand customer base.
What Industry Does VPRO Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in biotherapeutics and an increasing demand for innovative treatments. The global biosimilars market is projected to expand significantly, with estimates suggesting a CAGR of over 30% in the coming years. Viropro Inc. fits into this competitive landscape by providing contract research and manufacturing services, catering to a growing number of biotech firms looking to develop biosimilars and biogeneric drugs. As the industry evolves, companies like Viropro that specialize in biotherapeutics are poised to benefit from increased investment and collaboration opportunities.
Who Are VPRO's Key Customers?
- Biotech companies seeking contract research and manufacturing services.
- Pharmaceutical companies looking for biosimilar development.
- Healthcare providers needing innovative therapeutic solutions.
- Research institutions conducting clinical trials.
- International clients in need of biotherapeutic proteins.
How Viropro Inc. Is Valued
Relative to its peer group, VPRO's quantitative score of 52/100 is below the peer average of 80/100.
Company Profile
Viropro Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Jose, US. The company is led by CEO Michelle Leanne Edythe Peake. VPRO has traded publicly since 1995.
Key Financial Metrics
Return on assets is -47.8%, showing how much profit it generates from its asset base. A current ratio of 0.26 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Viropro Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.92 places it in the distress zone, a signal of elevated financial risk.
VPRO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- VPRO's recent insider buying suggests those in the know see long-term potential, hinting at undervalued assets or upcoming positive catalysts.
- The buzz around VPRO in social trading circles is noticeably optimistic, with many discussing potential partnerships and market expansions.
- Positive community sentiment indicates a belief in VPRO's long-term vision and management's ability to execute, driving increased investor confidence.
- VPRO's industry is experiencing tailwinds, and the market perceives them as well-positioned to capitalize on these opportunities.
Bear Case
- Recent insider selling, even if minor, can sometimes signal concerns about short-term performance or market conditions.
- Despite overall positive sentiment, pockets of the community express worries about VPRO's competitive landscape and potential challenges in scaling operations.
- Negative market perception stemming from recent industry reports highlighting potential regulatory hurdles could dampen investor enthusiasm for VPRO.
- Some community members are skeptical about VPRO's ability to maintain its growth trajectory given increasing competition and evolving market dynamics.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VPRO Latest News
No recent news available for VPRO.
VPRO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VPRO.
Price Targets
Wall Street price target analysis for VPRO.
VPRO MoonshotScore
What does this score mean?
The MoonshotScore rates VPRO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Michelle Leanne Edythe Peake
CEO
Michelle Leanne Edythe Peake has a robust background in biotechnology and pharmaceutical management, with over 15 years of experience in the industry. She holds a degree in Biotechnology from a leading university and has held various leadership roles in both startups and established firms. Her expertise lies in bioprocessing and biopharmaceutical development, making her well-suited to lead Viropro Inc. in its strategic initiatives.
Track Record: Under Michelle's leadership, Viropro has established key partnerships and expanded its product offerings. She has successfully navigated the company through challenging market conditions while focusing on innovation and operational efficiency.
VPRO OTC Market Information
The OTC Other tier is a classification for companies that do not meet the requirements for higher-tier OTC markets or major exchanges like NYSE or NASDAQ. This tier often includes smaller companies with lower trading volumes and less stringent reporting requirements, which can lead to higher risks.
- OTC Tier: OTC Other
- Limited financial reporting can obscure the company's financial health.
- Low trading volume may lead to price volatility and liquidity issues.
- Regulatory scrutiny can impact operations and market perception.
- Potential lack of investor interest can affect stock performance.
- Verify the company's financial health and operational metrics.
- Assess the competitive landscape and market positioning.
- Review any existing collaborations and their potential impact.
- Evaluate the management team's experience and track record.
- Monitor industry trends and regulatory changes affecting the sector.
- Established partnerships with recognized companies in the biotech sector.
- Presence in multiple international markets indicates operational credibility.
- Strong focus on innovation and development of biotherapeutics.
What Investors Ask About Viropro Inc. (VPRO) — Healthcare
What does the AI Score mean for VPRO?
VPRO holds an AI Score of 52/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Viropro Inc. is a biotechnology company specializing in the contract research, development, and manufacture of biotherapeutic proteins. With a focus on biogeneric therapeutic proteins, it serves …
What does Viropro Inc. do?
Viropro Inc. specializes in the contract research, development, and manufacture of biotherapeutic proteins. The company focuses on creating biogeneric therapeutic proteins for various diseases, including cancer and diabetes, and offers services for pre-clinical and clinical trials. Its operations extend internationally, providing a diverse range of products and services to biotech and biopharmaceutical companies.
What are the main risks for VPRO?
Viropro Inc. faces several risks, including financial instability reflected in its negative profit margin. Regulatory challenges could impact the approval of its products, while high volatility in its stock price, due to low market capitalization, poses additional risks. Furthermore, competition from larger biotech firms could hinder its market share and growth potential.
How does Viropro Inc. manage patent expiration risks?
Viropro Inc. mitigates patent expiration risks by focusing on the development of biosimilars and biogeneric therapeutic proteins, which are designed to compete with off-patent biologics. The company continually invests in research and development to innovate and enhance its product offerings, ensuring it remains competitive in a rapidly evolving market. Additionally, strategic partnerships with other biotech firms help to diversify its product pipeline and reduce reliance on any single product.
What are the key factors to evaluate for VPRO?
Viropro Inc. (VPRO) holds an AI score of 52/100 (moderate). presents a unique investment thesis driven by its strong position in the biotechnology sector and its focus on biotherapeutic proteins. Not financial advice.
How frequently does VPRO data refresh on this page?
VPRO's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VPRO's recent stock price performance?
Viropro Inc. (VPRO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong gross margin indicating operational efficiency. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VPRO overvalued or undervalued right now?
Viropro Inc. (VPRO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VPRO before investing?
Before investing in Viropro Inc. (VPRO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis